Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescence analysis of VHL was performed using 70% confluent log phase SH-SY5Y cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with VHL (Ig33) Mouse Monoclonal Antibody (MA513940) at 2ug/ml in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing cytoplasmic localization. Panel e shows the control without primary antibody. The images were captured at 60X magnification.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||A recombinant protein containing aa 1-213 of human VHL|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunocytochemistry (ICC)||2 µg/ml|
|Immunofluorescence (IF)||2 µg/ml|
|Immunohistochemistry (Paraffin) (IHC (P))||2-4 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13940 targets von Hippel-Lindau Protein in immunohistochemistry (paraffin) and immunofluorescence applications and shows reactivity with Human and mouse samples.
The MA5-13940 immunogen is a recombinant protein containing aa 1-213 of human VHL.
Molecular genetic studies suggest that VHL is a tumor-suppressor gene. Alterations in the von Hippel-Lindau (VHL) gene are correlated with a diverse group of neoplasms including hemangioblastoma, clear cell renal carcinoma (RCC), and pheochromocytoma. Two transcriptional elongation factors, Elongin B and C, are shown to bind in vitro and in vivo to a short, colinear region of the VHL protein (pVHL) that is frequently mutated in human tumors. It is proposed that pVHL functions in vivo as a negative regulator of transcription elongation.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
VHL and HIF-1¿: gene variations and prognosis in early-stage clear cell renal cell carcinoma.
MA5-13940 was used in immunohistochemistry - paraffin section to study the effect of genetic alterations and protein expression of Von Hipple-Lindau and the C1772T SNP of HIF-1alpha gene on prognosis in early-stage clear cell renal cell carcinoma
|Lessi F,Mazzanti CM,Tomei S,Di Cristofano C,Minervini A,Menicagli M,Apollo A,Masieri L,Collecchi P,Minervini R,Carini M,Bevilacqua G||Medical oncology (Northwood, London, England) (31:null)||2014|
The expression pattern of Von Hippel-Lindau tumor suppressor protein, MET proto-oncogene, and TFE3 transcription factor oncoprotein in renal cell carcinoma in Upper Egypt.
MA5-13940 was used in immunohistochemistry to investigate the expression of tumor suppressor genes in renal cell carcinoma in Upper Egypt
|Nagi FM,Omar AA,Mostafa MG,Mohammed EA,Abd-Elwahed Hussein MR||Ultrastructural pathology (35:79)||2011|
Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
MA5-13940 was used in immunohistochemistry to examine the prognostic significance of cell necrosis for nonmetastatic clear cell renal cell carcinoma
|Minervini A,Di Cristofano C,Gacci M,Serni S,Menicagli M,Lanciotti M,Salinitri G,Rocca CD,Lapini A,Nesi G,Bevilacqua G,Minervini R,Carini M||The Journal of urology (180:1284)||2008|
Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression.
MA5-13940 was used in immunohistochemistry to investigate the prognostic value of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma
|Di Cristofano C,Minervini A,Menicagli M,Salinitri G,Bertacca G,Pefanis G,Masieri L,Lessi F,Collecchi P,Minervini R,Carini M,Bevilacqua G,Cavazzana A||The American journal of surgical pathology (31:1875)||2007|
Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
MA5-13940 was used in immunohistochemistry to investigate the expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma
|Lee S,Garner EI,Welch WR,Berkowitz RS,Mok SC||Gynecologic oncology (106:311)||2007|
Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance.
MA5-13940 was used in immunohistochemistry to investigate the differentially expressed genes in salivary gland neoplasms
|Maruya S,Kim HW,Weber RS,Lee JJ,Kies M,Luna MA,Batsakis JG,El-Naggar AK||The Journal of molecular diagnostics : JMD (6:180)||2004|
elongin binding protein; Protein G7; pVHL; Von Hippel-Lindau disease tumor suppressor; von Hippel-Lindau syndrome homolog; von Hippel-Lindau syndrome protein homolog; von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase
HRCA1; pVHL; RCA1; VHL; VHL1; Vhlh